Improving Outcomes in Peripartum Cardiomyopathy with Vericiguat: A Clinical Case

Peripartum cardiomyopathy (PPCM) is a specific form of cardiomyopathy that manifests toward the end of pregnancy or within 5 months postpartum, characterized by a decrease in cardiac output due to impaired myocardial function. This condition has a multifactorial origin, influenced by genetic predispositions, inflammatory processes, autoimmunity, hormonal variations, and nutritional deficiencies. Prognosis varies among patients: while some recover completely within 6 months, others may develop chronic cardiac dysfunction requiring long-term treatment. Vericiguat, a soluble guanylate cyclase stimulator, has shown promising results in the treatment of heart failure with reduced ejection fraction. This drug works by enhancing the nitric oxide signaling pathway, promoting vasodilation, and improving myocardial function. Although the use of vericiguat in PPCM is not yet fully documented, its potential benefits suggest that it may represent a valid therapeutic option when standard therapies are insufficient for symptom control. We present the case of a 32-year-old woman with PPCM, initially undiagnosed, who developed severe symptoms of dyspnea, orthopnea, and peripheral edema postpartum. These symptoms were accompanied by a significant reduction in left ventricular ejection fraction. Following a suboptimal response to standard heart failure therapy, vericiguat was incorporated into her treatment regimen. In subsequent outpatient follow-ups, the patient's symptoms progressively improved, and left ventricular systolic function markedly increased. The patient became asymptomatic and was able to resume her normal daily activities. While this case suggests that vericiguat could be an effective adjunctive treatment for PPCM, it remains unclear whether these improvements were directly attributable to vericiguat or could have occurred with continued standard therapy alone. Further studies are needed to define the role of vericiguat in this condition.